Endpoint

Diastolic blood pressure (setting unspecified)

CAT:outcome/diastolic-blood-pressure-unspecified-settingreported in mm Hg34 findings from 20 compounds

What moved it

34 findings · 20 compounds · 15 null · by evidence strength

Compound	Direction	Findings	Strongest evidence
magnesium(2+)	down 3 · no effect 1	4	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
resveratrol	down 2 · no effect 2	4	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
curcumin	no effect	3	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
taurine	down	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Vitis vinifera	down	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
3,4-methylenedioxymethamphetamine	up	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
berberine	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
nitrate	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
NMN zwitterion	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
quercetin	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
rosuvastatin	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
melatonin	no effect	3	Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.
coenzyme Q10	no effect 1 · down 1	2	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
L-arginine	down	2	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
astaxanthin	no effect	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
caffeine	up	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
L-ascorbic acid	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
L-citrulline	no effect	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
L-cystine	up	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
rebaudioside A	no effect	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.

Reported to move it

19 findings

magnesium(2+) — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2
“Magnesium intake resulted in a reduction in systolic BP of -2.81 mm Hg (95% CI, -4.32 to -1.29) and diastolic BP by -2.05 mm Hg (95% CI, -3.23 to -0.88) compared with placebo.”
Quoted verbatim from Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials..
Study

meta-analysis
Dose

median 365 mg/d elemental magnesium (range 82.3-637 mg), median intervention period 12 weeks
Population

hypertensive and normotensive adults in randomized controlled trials of at least 4 weeks
Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2025PMID:41000008Permalink
resveratrol — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“The results illustrated a significant reduction in the DBP by resveratrol after removing these studies (WMD: −3.55 mmHg, 95% CI: −5.18, −1.93; P < 0.0001;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis..
Study

meta-analysis
Dose

8.1-3000 mg/day resveratrol across the pooled trials
Population

Adults with type 2 diabetes; secondary endpoint, pooled after excluding two high-heterogeneity trials, resveratrol vs placebo
Effect -3.55 mean difference, 95% CI -5.18 to -1.93
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602Permalink
rosuvastatin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“The patients treated with rosuvastatin in addition to antihypertensives had a significantly lower DBP (MD = −2.12 mmHg; 95% CI = −3.72 to −0.52; Pfixed-effects model = 0.009; I 2 = 0%, Pheterogeneity = 0.97) than the patients treated with antihypertensives alone.”
Quoted verbatim from Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies..
Study

meta-analysis
Duration

8 weeks
Dose

rosuvastatin 20 mg/day
Population

Patients with hypertension and dyslipidemia treated with rosuvastatin 20 mg/day plus antihypertensive agents (an ARB, or an ARB plus a calcium channel blocker), compared with the same antihypertensive background alone
Effect -2.12 mean difference, 95% CI -3.72 to -0.52
Antihypertensive effects of rosuvastatin in patients with hypertension and dyslipidemia: A systemic review and meta-analysis of randomized studies.2021PMID:34818350Permalink
3,4-methylenedioxymethamphetamine — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“The MDMA group higher SBP and DBP compared to the placebo group.”
Quoted verbatim from A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults..
Study

RCT
Dose

100 mg single oral dose
Population

Healthy adults aged 21-55 with prior recreational MDMA use, single 100 mg oral dose versus matching placebo in a parallel-group trial; blood pressure monitored at eight timepoints over the 6 hours after dosing
A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.2022PMID:35166140Industry fundedPermalink
NMN zwitterion — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“NMN supplementation was associated with a small but significant reduction in diastolic blood pressure (MD = −2.43 mmHg, 95% CI −4.21 to −0.66, p = 0.007, I2 = 0%).”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis..
Study

meta-analysis
Dose

250-2000 mg/day oral across included trials
Population

Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis of 11 comparisons
Effect -2.43 mean difference, 95% CI -4.21 to -0.66
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
taurine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect -1.509 mean difference, 95% CI -2.479 to -0.539
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink

Show the remaining 13

Vitis vinifera — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“Overall analyses found significant reductions for SBP (WMD = -6.077; 95% CI: -10.736 to -1.419; P = 0.011) and DBP (WMD = -2.803; 95% CI: -4.417 to -1.189; P = 0.001) after grape seed extract treatment.”
Quoted verbatim from The impact of grape seed extract treatment on blood pressure changes: A meta-analysis of 16 randomized controlled trials..
Study

meta-analysis
Population

Participants in 16 pooled randomized clinical trials (12 articles) of grape seed extract treatment
Effect -2.803 mean difference, 95% CI -4.417 to -1.189
The impact of grape seed extract treatment on blood pressure changes: A meta-analysis of 16 randomized controlled trials.2016PMID:27537554Permalink
taurine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“Taurine demonstrated a significant reduction in HR (weighted mean difference [WMD] = -3.579 bpm, 95% confidence interval [CI] = -6.044 to -1.114, p = 0.004), SBP (WMD = -3.999 mm Hg, 95% CI = -7.293 to -0.706, p = 0.017), DBP (WMD: -1.435 mm Hg, 95% CI: -2.484 to -0.386, p = 0.007), NYHA (WMD: -0.403, 95% CI: -0.522 to -0.283, p < 0.001), and a significant increase in LVEF (WMD: 4.981%, 95% CI: 1.556 to 8.407, p = 0.004).”
Quoted verbatim from Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis..
Study

meta-analysis
Population

Pooled 20 RCTs (808 participants) of taurine across healthy individuals, heart failure patients and other disease groups; all-population estimate
Effect -1.435 mean difference, 95% CI -2.484 to -0.386
Insights into the cardiovascular benefits of taurine: a systematic review and meta-analysis.2024PMID:39148075Permalink
quercetin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Combined analysis of 9 RCT arms revealed a significant reduction of DBP (WMD: −2.63 mm Hg, 95% CI: −3.26, −2.01, P<0.001) following supplementation with quercetin (Figure lower part).”
Quoted verbatim from Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials..
Study

meta-analysis
Population

Adults in 7 placebo-controlled randomised trials (9 treatment arms, parallel and crossover), mostly without hypertension, quercetin 100 to 1000 mg/day for 4 to 10 weeks
Effect -2.63 mean difference, 95% CI -3.26 to -2.01
Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2016PMID:27405810Permalink
Vitis vinifera — decreases
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Findingreplicated ×1
“Our results indicated that GSE decreased resting DBP (75 ± 2 vs. 71 ± 3) and MAP (91 ± 2 vs. 88 ± 3) compared to the placebo (DBP:71 ± 3 vs. 74 ± 3; MAP: 89 ± 2 vs. 90 ± 2).”
Quoted verbatim from Effect of 7-day dietary supplementation with grape seed extract on cardiac autonomic and hemodynamic responses in elevated and stage 1 hypertension..
Study

crossover
Population

Males with elevated and stage 1 hypertension in a double-blind placebo-controlled cross-over trial of short-term dietary grape seed extract supplementation with a 1-week wash-out
Effect of 7-day dietary supplementation with grape seed extract on cardiac autonomic and hemodynamic responses in elevated and stage 1 hypertension.2025PMID:40341867Permalink
coenzyme Q10 — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“Treatment with coenzyme Q10 in subjects with systolic BP (SBP) > 140 mmHg or diastolic BP (DBP) > 90 mmHg resulted in mean decreases in SBP of 11 mmHg (95% CI 8, 14) and DBP of 7 mmHg (95% CI 5, 8).”
Quoted verbatim from Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension..
Study

meta-analysis
Population

adults with primary hypertension (SBP >140 mmHg or DBP >90 mmHg); Cochrane meta-analysis of 3 RCTs, 96 participants, coenzyme Q10 versus placebo for at least 3 weeks
Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension.2009PMID:19821418Permalink
L-arginine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1
“The pooled analysis demonstrated significant decreases in SBP (WMD = -6.40 mmHg; 95% CI: -8.74, -4.05; P < 0.001) and DBP (WMD = -2.64 mmHg; 95% CI: -3.94, -1.40; P < 0.001) after l-arginine supplementation.”
Quoted verbatim from Effect of l-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-analysis of Randomized Clinical Trials..
Study

meta-analysis
Population

adults; overall pooled estimate across all trials, not a dose or duration stratum
Effect of l-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-analysis of Randomized Clinical Trials.2022PMID:34967840Permalink
magnesium(2+) — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2
“The weighted overall effects indicated that the magnesium-supplementation group had a significantly greater reduction in both SBP (SMD: -0.20; 95% CI: -0.37, -0.03) and DBP (SMD: -0.27; 95% CI: -0.52, -0.03) than did the control group.”
Quoted verbatim from The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials..
Study

meta-analysis
Participants

543
Dose

365-450 mg/d elemental magnesium
Population

Individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases; 11 RCTs, all of which reported BP at baseline and end of trial
The effect of magnesium supplementation on blood pressure in individuals with insulin resistance, prediabetes, or noncommunicable chronic diseases: a meta-analysis of randomized controlled trials.2017PMID:28724644Permalink
magnesium(2+) — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2
“Although not all individual trials showed significance in BP reduction, combining all trials did show a decrease in SBP of 3-4 mm Hg and DBP of 2-3 mm Hg, which further increased with crossover designed trials and intake >370 mg/day.”
Quoted verbatim from Effect of magnesium supplementation on blood pressure: a meta-analysis..
Study

meta-analysis
Dose

120-973 mg elemental magnesium/day (mean 410 mg)
Population

Adults in randomized (including crossover) trials of magnesium supplementation for blood pressure
Effect of magnesium supplementation on blood pressure: a meta-analysis.2012PMID:22318649Permalink
resveratrol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1
“Resveratrol intervention exerted significant reductions in systolic blood pressure (SBP) and diastolic blood pressure (DBP) in subjects with type 2 diabetes mellitus (T2DM).”
Quoted verbatim from Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

subjects with type 2 diabetes mellitus (T2DM)
Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials.2018PMID:28933578Permalink
L-cystine — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“Using the same confounding factors, multivariate‐adjusted linear regression analysis confirmed the positive association of L‐cystine levels with SBP and DBP (β = 2.66, p =.015 for SBP; β = 2.50, p =.002 for DBP) (Table 5).”
Quoted verbatim from Blood L-cystine levels positively related to increased risk of hypertension..
Study

case-control
Population

Adults aged 18-75 years recruited at Heilongjiang Provincial Hospital, 22 hypertensive and 63 normotensive; endogenous fasting plasma L-cystine by non-targeted LC-MS/MS metabolomics, adjusted for age, sex, BMI, fasting glucose, triglycerides and HDL-c
Blood L-cystine levels positively related to increased risk of hypertension.2024PMID:39403054Permalink
L-arginine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1
“This study demonstrates L-arginine supplementation is superior to placebo in lowering diastolic pressure and prolonging pregnancy in patients with gestational hypertension with or without proteinuria, but the effect on lowering systolic pressure and increasing neonatal weight was not statistically significant.”
Quoted verbatim from Arginine supplementation for improving maternal and neonatal outcomes in hypertensive disorder of pregnancy: a systematic review..
Study

meta-analysis
Population

patients with gestational hypertension with or without proteinuria
Arginine supplementation for improving maternal and neonatal outcomes in hypertensive disorder of pregnancy: a systematic review.2014PMID:23435582Permalink
caffeine — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“The pooled of 11 effect sizes analysis of 8 studies demonstrated significant increases in SBP (WMD:1.94 mmHg; 95%CI:0.52, 3.35; p = 0.007) and DBP (WMD:1.66 mmHg; 95% CI:0.75, 2.57; p = 0.000) after caffeine supplementation.”
Quoted verbatim from The effects of caffeine supplementation on blood pressure in adults: A systematic review and dose-response meta-analysis..
Study

meta-analysis
Population

adults ≥18 years, dose-response meta-analysis of randomized controlled trials of caffeine supplementation
Effect 1.66 mean difference, 95% CI 0.75 to 2.57
The effects of caffeine supplementation on blood pressure in adults: A systematic review and dose-response meta-analysis.2023PMID:38057002Permalink
L-ascorbic acid — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“In short-term trials, vitamin C supplementation reduced SBP and DBP.”
Quoted verbatim from Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials..
Study

meta-analysis
Dose

median 500 mg/d oral
Population

Adults in randomized trials of oral vitamin C supplementation versus concurrent controls (29 trials in the primary analysis, median dose 500 mg/d, median duration 8 wk)
Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials.2012PMID:22492364Permalink

Measured, no effect detected

15 findings

curcumin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2
“Five studies assessed changes in blood pressure indicating no significant effect of curcumin supplementation on both SBP and DBP with pooled MD (95% CI) of −0.29 (−0.91, 0.34) and −0.02 (−0.55, 0.52) mmHg, respectively, see Supplementary Appendix V–W.”
Quoted verbatim from An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand..
Study

meta-analysis
Dose

80–3000 mg/day pooled across bioavailability-enhanced forms (80–1000 mg/day), curcumin extracts (1500 mg/day) and turmeric powder (2000–3000 mg/day)
Population

Adults with MAFLD (NAFLD/NASH); 5 RCTs; blood pressure was an additional (secondary) outcome and the acquisition protocol is not recoverable from the pooled estimate
Effect -0.02 mean difference, 95% CI -0.55 to 0.52
An updated meta-analysis of effects of curcumin on metabolic dysfunction-associated fatty liver disease based on available evidence from Iran and Thailand.2023PMID:37037891Permalink
curcumin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×2
“Meta‐analysis of 16 effect sizes demonstrated no significant alteration in DBP following supplementation of curcumin/turmeric compared to control groups (WMD: −1.20 mmHg; 95% CI: −2.84 to 0.44; p = 0.15) (Figure.”
Quoted verbatim from Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials..
Study

meta-analysis
Population

adults with prediabetes or type 2 diabetes; primary endpoint
Effect -1.2 mean difference, 95% CI -2.84 to 0.44
Antihypertensive Effects of Curcumin/Turmeric Supplementation in Prediabetes and Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.2026PMID:41388744Permalink
nitrate — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“No significant effects of nitrate supplementation were observed on body weight, BMI, or diastolic blood pressure (DBP).”
Quoted verbatim from The effect of dietary nitrate on weight management: a systematic review and meta-analysis..
Study

meta-analysis
Population

adults with obesity
The effect of dietary nitrate on weight management: a systematic review and meta-analysis.2026PMID:42130877Permalink
berberine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“The effect of BBR supplementation on DBP was non-significant (WMD = −2.74 mmHg; 95%CI, −5.63 to 0.15; P = 0.063).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis..
Study

meta-analysis
Population

Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS, hypertension and other populations)
Effect -2.74 mean difference, 95% CI -5.63 to 0.15
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
melatonin — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1
“Mean Daytime Diastolic Blood Pressure (DBP) (SECONDARY, mmHg) -- NCT01114360: Melatonin 85.7 +/-1.6 (n=36) vs Placebo 86.2 +/-1.7 (n=36); difference -0.5; p=0.89, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study.
Study

crossover
Participants

72
Population

Hypertension; 18 Years+
Effect -0.5 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360Permalink
melatonin — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1
“Mean Nighttime Diastolic Blood Pressure (DBP) (PRIMARY, mmHg) -- NCT01114360: Melatonin 76 +/-1.7 (n=36) vs Placebo 76.2 +/-1.8 (n=36); difference -0.2; p=0.75, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study.
Study

crossover
Participants

72
Population

Hypertension; 18 Years+
Effect -0.2 mean difference
Melatonin and Nighttime Blood Pressure in African Americans-8 mg Study2015NCT01114360Permalink

Show the remaining 9

melatonin — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull resultreplicated ×1
“Mean Daytime Diastolic Blood Pressure (DBP) (SECONDARY, mmHg) -- NCT01114373: Melatonin 85.3 +/-1.8 (n=36) vs Placebo 86.6 +/-1.8 (n=36); difference -1.3; p=0.12, no significant difference”
Quoted verbatim from Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study.
Study

crossover
Participants

72
Population

Hypertension; 18 Years+
Effect -1.3 mean difference
Melatonin and Nighttime Blood Pressure in African Americans--24 mg Study2015NCT01114373Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“For diastolic blood pressure we performed a random-effects meta-analysis, which showed no evidence of effect of CoQ10 supplementation when these two small trials were pooled (MD -1.62 mmHg, 95% CI -5.2 to 1.96).”
Quoted verbatim from Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease..
Study

meta-analysis
Population

adults at high risk of cardiovascular disease without a diagnosis of CVD; pooled analysis of two small RCTs
Effect -1.62 mean difference, 95% CI -5.2 to 1.96
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.2014PMID:25474484Permalink
L-citrulline — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“Systolic blood pressure (BP) was higher at delivery in the citrulline group compared with the control group (P = 0.015), whereas the diastolic BP showed no difference.”
Quoted verbatim from Oral citrulline supplementation in pregnancies with preeclampsia: a multicenter, randomized, double-blind clinical trial..
Study

RCT
Population

pregnant women with monofetal preeclampsia; blood pressure measured at delivery
Oral citrulline supplementation in pregnancies with preeclampsia: a multicenter, randomized, double-blind clinical trial.2025PMID:39638148Permalink
curcumin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2
“There was no significant change in HbA1C, plasma insulin, QUICKI, HDL, SBP, DBP, CRP, TNF-α and WC after curcumin therapy.”
Quoted verbatim from Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials..
Study

meta-analysis
Population

adults with non-alcoholic fatty liver disease (NAFLD)
Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials.2024PMID:38232906Permalink
astaxanthin — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“Current study revealed that astaxanthin consumption was not associated with FBS, HbA1c, TC, LDL-C, TG, BMI, BW, DBP, and SBP.”
Quoted verbatim from The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

adults; meta-analysis of randomized controlled trials of astaxanthin supplementation (14 studies)
The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials.2020PMID:32755613Permalink
rebaudioside A — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“Compared with placebo, rebaudioside A did not significantly alter resting, seated SBP, DBP, mean arterial pressure (MAP), heart rate (HR) or 24-h ambulatory blood pressures responses.”
Quoted verbatim from The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure..
Study

RCT
Duration

4 weeks
Dose

1000 mg/day rebaudioside A for 4 weeks
Population

healthy adults with normal and low-normal blood pressure
The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure.2008PMID:18555574Permalink
resveratrol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1
“The present meta-analysis indicates that resveratrol consumption significantly decreases the SBP level at the higher dose, while resveratrol has no significant effects on DBP levels.”
Quoted verbatim from Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

Meta-analysis of 6 randomized controlled trials of resveratrol supplementation (247 subjects total); overall estimate across all doses
Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials.2015PMID:24731650Permalink
magnesium(2+) — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“Neither systolic nor diastolic BP was significantly changed.”
Quoted verbatim from Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials..
Study

meta-analysis
Dose

15 mmol/day (360 mg/day) oral magnesium, median
Population

Adults with type 2 diabetes in randomized double-blind controlled trials of oral magnesium supplementation
Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials.2006PMID:16978367Permalink
resveratrol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1
“Also, the two groups showed no significant differences in diastolic blood pressure (DBP), HDL, or oxidative stress markers.”
Quoted verbatim from Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients..
Study

RCT
Duration

2 months
Population

patients undergoing coronary artery bypass grafting (CABG)
Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients.2025PMID:40676400Permalink

How it is measured

Brachial diastolic blood pressure by cuff sphygmomanometry or a validated automated device, where the source does not record the acquisition protocol. The defining property of this endpoint is that the acquisition conditions cannot be recovered from the reported value.